BRIEF-Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106

June 22 (Reuters) – Antengene Corp Ltd: * ENTERS EXCLUSIVE LICENSE AGREEMENT WITH K2 THERAPEUTICS FOR ATG-106 * TO RECEIVE ABOUT $20 MILLION UPFRONT AND NEAR-TERM CONSIDERATION Further company

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)